Indian Government moves closer to complying with EU API rules

Home/Policies & Legislation | Posted 14/06/2013 post-comment0 Post your comment

On 23 May 2013, the Indian Government announced that it had issued finalized guidelines for drugmakers to comply with a European Union (EU) directive on standards for import of active pharmaceutical ingredients (APIs) into the EU that takes effect on 2 July 2013.

API V13C22

Under the new rules, which are part of the EU’s Falsified Medicines Directive, India must certify that bulk drugs, or active pharmaceutical ingredients (APIs), meet European good manufacturing practices (GMP) standards. The current regulation requires that the certification be done by the country to which the APIs are being exported.

Although concern has been expressed that some countries may not be able to put the necessary systems in place by July 2013 to be able to issue written confirmation of GMP compliance, India has alleviated these concerns. In fact, the Indian Government has stated that it ‘is optimistic that its pharma industry would be able to meet regulatory requirements within the given time frame’.

The government is also planning to initiate an online application filing and tracking system to speed up the process and bring increased transparency to the system.

Related articles

China and India still to comply with new EU API rules

EU API law causing concern among API producers

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

Source: The Economic Times India, Indian Business Standard

comment icon Comments (0)
Post your comment
Related content
NPRA Malaysia trials new timelines for variation applications
24-AA011041
Home/Policies & Legislation Posted 05/11/2024
China’s NMPA expands global ties with the Netherlands and Indonesia
China CFDA NMPA
Home/Policies & Legislation Posted 04/09/2024
Japan's PMDA expands influence with new office in Thailand
Conference V14A17
Home/Policies & Legislation Posted 06/08/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010